WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- Investor RelationsAbout Us
- News & ResourcesAbout Us
WuXi XDC Included in MSCI China All Share Index
(Shanghai, China, August 8, 2025) – WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today announced its inclusion in the...Novel Conjugation and Payload-Linker Technologies for Next Generation ADCs
WuXi XDC and Mabsoft Therapeutics Form Strategic Partnership to Accelerate Development of Next-Generation Immune-Stimulating Antibody Conjugates (ISACs)
Shanghai, April 3, 2025 – WuXi XDC Cayman Inc. (“WuXi XDC”, stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate market, today announced a strategic partnership with Mabsoft...WuXi XDC Achieved Another Remarkable Year with Extraordinary Business Performance and Financial Results for 2024
Revenue increased by 90.8% YoY to RMB 4,052 million Gross profit grew by 121.6% YoY to RMB 1,240 million, with its margin of 30.6%, a 4.3 percentage points increase compared to that of 2023 Net profit surged by 277.2% YoY to RMB 1,070 million, with its margin of...
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?